CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-568.53	-581.6	-366.25	-153.61	-650.18	377.66
Depreciation & Amortization	19.06	19.48	19.26	19.84	24.17	17.95
Stock-Based Compensation	68.61	72.5	86.57	81.03	97.95	102.39
Other Adjustments	31.15	72.73	-38.62	-14.05	12.47	14.11
Change in Receivables	-	25	175	-200	0.31	-0.16
Changes in Accounts Payable	-11.12	44.89	-27.28	-20.25	5.16	37.51
Changes in Unearned Revenue	-	-0.4	-1.95	5.79	-1.01	-0.78
Changes in Other Operating Activities	12.74	2.39	10.5	20.87	15.39	-9.71
Operating Cash Flow	-399.96	-345.01	-142.77	-260.38	-495.74	538.97
Capital Expenditures	-1.21	-0.91	-1.9	-9.47	-37.19	-81.71
Purchases of Intangible Assets	-12.5	-25	-	-2.5	-	-
Purchases of Investments	-1,563	-1,018	-1,486	-1,066	-1,418	-1,509
Proceeds from Sale of Investments	1,166	1,012	1,208	1,453	1,196	555.6
Investing Cash Flow	-422.79	-31.81	-280.48	374.65	-258.66	-1,035
Long-Term Debt Issued	600	-	-	-	-	-
Net Long-Term Debt Issued (Repaid)	600	-	-	-	-	-
Issuance of Common Stock	420.87	426.03	331.98	62.66	38.59	250.95
Net Common Stock Issued (Repurchased)	420.87	426.03	331.98	62.66	38.59	250.95
Other Financing Activities	-13.53	-	-	-	-	-
Financing Cash Flow	1,007	426.03	331.98	62.66	38.59	250.95
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.02	0.1	-0.02	0.07	-0.08	-0.01
Net Cash Flow	184.61	49.3	-91.29	177.01	-715.88	-245.52
Free Cash Flow	-401.18	-345.93	-144.68	-269.85	-532.93	457.27
FCF Margin	-9777.63%	-	-	-	-44484.90%	49.98%
Free Cash Flow Per Share	-4.34	-3.85	-1.71	-3.41	-6.85	5.69
Levered Free Cash Flow	50.94	152.05	102.53	88.6	-643.65	340.93
Unlevered Free Cash Flow	-630.82	65.45	-1.37	16.78	-666.3	334.96

Updated May 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q